MENU

ALMS Alumis Inc. Forecast, Technical & Fundamental Analysis

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases... Show more

ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
View a ticker or compare two or three
ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XRPR10.471.19
+12.78%
REX-Osprey XRP ETF
BIB83.721.06
+1.29%
ProShares Ultra Nasdaq Biotechnology
EUAD41.580.45
+1.09%
Select STOXX Europe Aerospace & Defense ETF
ICLN21.030.17
+0.80%
iShares Global Clean Energy ETF
DIAL18.190.04
+0.22%
Columbia Diversified Fixed Inc Allc ETF

ALMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALMS has been loosely correlated with MRNA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALMS jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMS
1D Price
Change %
ALMS100%
+15.55%
MRNA - ALMS
34%
Loosely correlated
+0.54%
ZNTL - ALMS
33%
Loosely correlated
+6.53%
ARVN - ALMS
32%
Poorly correlated
+6.91%
DRUG - ALMS
31%
Poorly correlated
-1.01%
ACRV - ALMS
29%
Poorly correlated
+2.78%
More
Alumis (ALMS) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com